Sermorelin: The Physiologic Pituitary Signal

The short version

Sermorelin is a synthetic 29-amino-acid peptide that copies the first 29 residues of endogenous growth hormone-releasing hormone. That stretch is the shortest fragment that binds the GHRH receptor on the pituitary gland with full activity. When it binds, it prompts the pituitary to release the body's own growth hormone in the normal pulsatile pattern, with intact feedback through somatostatin and IGF-1 keeping levels in the physiologic range ^[1].

Here is the honest picture. Sermorelin was once FDA-approved as Geref for pediatric growth hormone deficiency — meaning human trial data exist from the 1990s ^[5]. It was withdrawn from the US market in 2008 for commercial reasons, not safety or efficacy problems, and it is now compounded under FDA's 503A Category 1 policy ^[1][3]. Off-label adult anti-aging use is widely marketed but the evidence for that application is limited and explicitly flagged as "not yet ready for prime time" by a 2008 Annals of Internal Medicine editorial ^[3]. This page summarizes what was studied; it lists no human dose and provides no medical advice.

What it is

Sermorelin is the synthetic 1-29 N-terminal fragment of human growth hormone-releasing hormone (hGHRH), also designated GHRH(1-29)NH2 or GRF(1-29)NH2 — the "NH2" suffix indicating a C-terminal amide group that confers metabolic stability. Its formal INN is sermorelin acetate. The 1-29 fragment is the minimum sequence required for full agonist activity at the GHRH receptor; the remaining 15 residues of endogenous GHRH(1-44) contribute only marginally to receptor binding.

Sermorelin was formerly sold as Geref (NDA 020443), approved for idiopathic GH deficiency and short stature in children. That product was discontinued in 2008 for commercial reasons; the compound was not withdrawn for safety or efficacy concerns. It is now available through compounding pharmacies as a Category 1 bulk drug substance under FDA's interim 503A policy (final guidance January 2025).

How it works

Sermorelin binds the growth hormone-releasing hormone receptor (GHRH-R) on anterior-pituitary somatotrophs — the cells that make and release GH. Receptor engagement activates Gs, which stimulates adenylate cyclase to raise intracellular cAMP, activating protein kinase A (PKA). PKA phosphorylates transcription factors that drive GH gene expression and triggers secretory vesicle exocytosis, releasing GH in a pulse ^[1].

The critical distinction from exogenous GH therapy is that the pituitary's own somatostatin inhibition and IGF-1 negative feedback remain active throughout. Sermorelin therefore amplifies the body's existing pulsatile GH rhythm rather than bypassing it — maintaining physiologic GH patterns and preventing the continuous GH elevation seen with recombinant GH ^[4]. A single intravenous dose elicited dose-dependent GH release at doses as low as 0.25 mcg/kg in healthy men, with GH remaining elevated approximately 3 hours despite rapid peptide clearance ^[6].

What the research shows

Pediatric GH deficiency (clinical trial data). The approved indication is grounded in a multicenter trial in prepubertal GH-deficient children. Once-daily subcutaneous GHRH(1-29) accelerated linear growth, with first-year height velocity rising from approximately 4.1 cm/year at baseline to roughly 7-8 cm/year on treatment, without excessive IGF-1 generation ^[5].

Reversal of age-related GH decline. In healthy older men (mean age 68), twice-daily subcutaneous sermorelin 0.5 mg or 1.0 mg for 14 days produced dose-related increases in 24-hour GH and IGF-1; at the high dose, GH and IGF-1 parameters no longer differed significantly from those of young men, with no change in fasting glucose ^[7].

Pharmacokinetics. Intravenous GHRH(1-29) in 30 healthy men elicited maximal GH release at 1-2 mcg/kg; despite rapid plasma elimination, GH remained elevated for approximately 3 hours. Intranasal bioavailability was only 3-5%, a finding relevant to the route of administration ^[6].

Broader class context. A 2025 Nature Reviews Endocrinology review synthesizes the pharmacology of GHRH and its analogs — the class that includes sermorelin, tesamorelin, and CJC-1295 — covering receptor signaling, the GH/IGF-1 axis, and both therapeutic and investigational applications. It is the authoritative current framing of the field ^[1].

GHRH for cognition. A 2012 randomized controlled trial in 152 older adults (including those with mild cognitive impairment) found that 20 weeks of daily subcutaneous GHRH analog produced a favorable effect on cognition (executive function P=0.005) alongside a 117% increase in IGF-1 and a 7.4% reduction in percent body fat. This was a tesamorelin study, but the cognitive mechanism is relevant to the sermorelin class ^[2].

Anti-aging use: the evidence gap. A 2008 Annals of Internal Medicine editorial by Blackman explicitly judged GH-secretagogue use for aging "not yet ready for prime time" based on the evidence available, a caution that remains applicable to unapproved adult uses ^[3]. A Walker 2006 editorial in Clinical Interventions in Aging makes the case that sermorelin's preservation of pulsatile feedback may make it preferable to recombinant GH for adult GH insufficiency, but notes this remains an argument, not established evidence ^[4].

Reported effects, cautions and safety

The cautions that follow come from the cited literature, not anecdotal testimony.

• Anti-aging evidence is limited. Use of sermorelin for adult anti-aging, body composition, or wellness purposes is widely marketed but lacks the controlled long-term evidence that supported the pediatric GH-deficiency approval. The leading editorial explicitly called this use not yet evidence-justified ^[3].
• GH/IGF-1 and oncologic risk. GH and IGF-1 are mitogenic growth factors. Chronically raising them is theorized to carry oncologic risk; this is a recognized caution for any GH-axis intervention, even when acting through the body's own feedback-regulated pulsatile secretion ^[1].
• Compounding status is nuanced. Sermorelin's Category 1 status under 503A means it occupies a distinct regulatory position from GH secretagogues reviewed at the October 2024 Pharmacy Compounding Advisory Committee (ipamorelin, ibutamoren, kisspeptin-10). These should not be conflated.
• Oral, sublingual, and troche products. These routes are widely criticized as ineffective because peptides are degraded in the GI tract; the 3-5% intranasal bioavailability data ^[6] are consistent with that concern.
• WADA prohibition. GHRH analogs including sermorelin are prohibited in sport under the WADA Prohibited List (S2). Athletes face anti-doping consequences.

Where it fits in GH-axis research

Among the three peptides on this desk, sermorelin is the lead — the one with the most clinical history, a former approved indication, and human data extending back to 1992. Its short half-life means frequent dosing; its pituitary-mediated mechanism means preserved feedback. Where tesamorelin has the strongest current regulatory standing and the most rigorous RCT evidence, and CJC-1295 extends half-life at the cost of leaving the approved pathway entirely, sermorelin sits in the middle of the clinical spectrum: more evidence than CJC-1295, narrower current approval than tesamorelin. See the comparison page for how the three line up.